Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department

Clinical Biochemistry

Volumn 43, Issue 9, 2010, Pages 714-719

  Dieplinger, Benjamin ^a   Gegenhuber, Alfons ^a   Kaar, Gerhard ^a   Poelz, Werner ^b   Haltmayer, Meinhard ^a   Mueller, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Emergency department; Heart failure; Mortality; Natriuretic peptides; Outcome; Pneumonia; Prognosis; Soluble ST2

Indexed keywords

ADIPONECTIN; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CHROMOGRANIN A; COPEPTIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; INTERLEUKIN 1 RECEPTOR TYPE II; PEPTIDE; PROADRENOMEDULLIN; PROGUANYLIN; PROUROGUANYLIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DYSPNEA; EMERGENCY WARD; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVOR; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHROMOGRANIN A; DYSPNEA; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN PRECURSORS; RECEPTORS, CELL SURFACE; RISK FACTORS; SURVIVAL RATE;

EID: 77952957535     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.02.002     Document Type: Article

References (38)

1. Michelson E., Hollrah S. Evaluation of the patient with shortness of breath: an evidence based approach. Emerg. Med. Clin. North Am. 1999, 17:221-237.
2. Manning H.L., Schwartzstein R.M. Pathophysiology of dyspnea. N. Engl. J. Med. 1995, 333:1547-1553.
3. Mulrow C.D., Lucey C.R., Farnett L.E. Discriminating causes of dyspnea through clinical examination. J. Gen. Intern. Med. 1993, 8:383-392.
4. Wasserman K. Dyspnea on exertion. Is it the heart or the lungs. JAMA 1982, 248:2039-2043.
5. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am. J. Respir. Crit. Care Med. 1999, 159:321-340. No authors.
6. Altose M.D. Assessment and management of breathlessness. Chest 1985, 88:77S-83S.
7. Hawkins N.M., Petrie M.C., Jhund P.S., et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur. J. Heart Fail. 2009, 11:130-139.
8. Fonarow G.C., Adams K.F., Abraham W.T., et al. ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580.
9. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350:1005-1012.
10. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997, 336:243-250.
11. Dieplinger B., Gegenhuber A., Haltmayer M., et al. Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in shortness-of-breath patients. Heart 2009, 95:1508-1513.
12. Mueller T., Gegenhuber A., Poelz W., et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005, 91:606-612.
13. Gegenhuber A., Mueller T., Dieplinger B., et al. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin. Chim. Acta 2006, 370:174-179.
14. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001, 163:1730-1754.
15. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur. Respir. J. 2003, 21:46S-53S.
16. Gonzales R., Sande M.A. Uncomplicated acute bronchitis. Ann. Intern. Med. 2000, 133:981-991.
17. Emond S.D., Camargo C.A. Nowak RM. 1997 National Asthma Education and Prevention Program guidelines: a practical summary for emergency physicians. Ann. Emerg. Med. 1998, 31:579-589.
18. Cleland J.G., Swedberg K., Follath F., et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe: Part 1. Patient characteristics and diagnosis. Eur. Heart J. 2003, 24:442-463.
19. Rutten F.H., Cramer M.J., Lammers J.W., et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination?. Eur. J. Heart Fail. 2006, 8:706-711.
20. Lee D.S., Austin P.C., Rouleau J.L., et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003, 290:2581-2587.
21. Macchia A., Monte S., Romero M., et al. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur. J. Heart Fail. 2007, 9:942-948.
22. Thomsen R.W., Kasatpibal N., Riis A., et al. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J. Gen. Intern. Med. 2008, 23:1407-1413.
23. Christ-Crain M., Morgenthaler N.G., Stolz D., et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit. Care 2006, 10:R96.
24. Katan M., Müller B., Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008, 12:117.
25. Brunner M., Krenn C., Roth G., et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 2004, 30:1468-1473.
26. Gombos T., Förhécz Z., Pozsonyi Z., et al. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm. Res. 2009, 58:298-305.
27. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N. Engl. J. Med. 2003, 348:1134-1149.
28. Tomoda K., Yoshikawa M., Itoh T., et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 2007, 132:135-140.
29. Daniels L.B., Maisel A.S. Natriuretic peptides. J. Am. Coll. Cardiol. 2007, 50:2357-2368.
30. Gegenhuber A., Struck J., Dieplinger B., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict one-year mortality in patients with acute destabilized heart failure. J. Card. Fail. 2007, 13:42-49.
31. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug. Discov. 2008, 7:827-840.
32. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190.
33. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 2008, 14:732-738.
34. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin. Chim. Acta 2009, 409:33-40.
35. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 2007, 50:607-613.
36. Mueller T., Dieplinger B., Gegenhuber A., et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 2008, 54:752-756.
37. Dieplinger B., Gegenhuber A., Struck J., et al. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin. Chim. Acta 2009, 400:91-96.
38. Zhang D., Lavaux T., Voegeli A.C., et al. Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin. Chem. 2008, 54:1497-1503.